CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Eculizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01192399
NCT01192399Phase 2Completed
CompareCT.gov

Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Alexion Pharmaceuticals, Inc.·interventional·Posted Sep 1, 2010·Updated Mar 13, 2018

In Brief

A Phase 2 clinical trial evaluating Eculizumab for Paroxysmal Nocturnal Hemoglobinuria. Completed, enrolled 29 participants.

Detailed Summary

A study to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Nocturnal Hemoglobinuria
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 1, 2010
Enrollment StartNov 1, 2007
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.8 years ago

Interventions

Eculizumabbiological